Translational and phase I evaluation of AZD0292, a novel, half-life extended anti-Pseudomonal Psl-PcrV bispecific monoclonal antibody.

Authors

Engin L, Camille Riff, Antonio DiGiandomenico, Fred Reid, Liesel Dsilva, Margaret Kehl, John Kim, Mun Mun Patnaik, Ashley Elaine Keller, Rikard Pehrson, Sanna Rosengren, Jieqiang Zhou, Marianna Stamou, Huixia Zhang, Patricia C Ryan, Richard Baldry, Gabriel Abreu, Mushtaq Husain, Karen Cartwright, Isabelle de Mendez, Ronald Goldwater, Wayne Brailsford, Rod Hughes

Published in

The Journal of infectious diseases. Oct 09, 2026. Epub Oct 09, 2026.

Abstract

Chronic Pseudomonas aeruginosa airway colonization in bronchiectasis (BE) is associated with frequent exacerbations. Bispecific antibody AZD0292, targeting P. aeruginosa Psl and PcrV, was engineered from gremubamab with a Fc N3Y substitution to extend half-life and is being developed to reduce exacerbations in BE with chronic P. aeruginosa colonization.
Preclinical studies assessed opsonophagocytic killing and anti-cytotoxicity assays, repeat-dose toxicology with ex vivo pharmacodynamic analyses in cynomolgus monkeys, and pharmacokinetics in human FcRn transgenic mice. In Phase I, healthy adults were randomized to receive a single dose of AZD0292 (n =24) or placebo (n = 8) in 4 cohorts (100-2,000 mg) and followed for 61 days or 161 days in cohort 4. Endpoints included safety, pharmacokinetics, immunogenicity, and exploratory cytokine/complement assessments.
AZD0292 demonstrated comparable functional activity to gremubamab, an approximately 55% lower clearance in transgenic mice, and retained anti-P. aeruginosa activity in cynomolgus monkey serum after repeated dosing. In Phase I, AZD0292 was generally well tolerated. Mild/moderate infusion-related reactions occurred only at higher doses and were managed with routine clinical measures. Transient cytokine increases were observed after dosing, with no meaningful complement activation. Pharmacokinetics were approximately dose-dependent but slightly less than dose-proportional across 100-2,000 mg. Geometric mean half-life ranged from 24 to 47 days, though estimates are provisional given small cohort sizes and limited follow-up. No treatment-emergent anti-drug antibodies were detected.
These results support further clinical development of AZD0292 for reduction of exacerbations in BE with chronic P. aeruginosa colonization, with pharmacokinetics requiring confirmation in the target patient population.

PMID:
42853976
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.